This article first appeared on GuruFocus .
Release Date: November 04, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Alpha Teknova Inc ( NASDAQ:TKNO ) delivered record revenue of $12.2 million, up 22% year-over-year, marking the second consecutive quarter of record revenue and the first time exceeding 20% growth in over four years.
-
Clinical Solutions revenue surged 86% to $3.2 million, driven by higher average revenue per customer and an increased number of customers, with expectations for continued growth as customers advance through clinical trials.
-
Gross margin expanded significantly to 38.0% from 30.7% in the prior year, primarily due to higher revenue and better fixed cost absorption, with further improvement expected as revenue scales.
-
The company raised $46 million in equity capital (net proceeds ~$43 million) to strengthen the balance sheet, providing flexibility for tuck-in acquisitions and attracting institutional investors, without needing capital to become cash flow positive.
-
New product launches, BuildTek and Filtek, are gaining traction: BuildTek generated over 140 quote requests from 100+ organizations, with 40% repeat use, and Filtek orders are over 60% GMP-grade, positioning Alpha Teknova Inc ( NASDAQ:TKNO ) for growth in clinical and commercial manufacturing.
Negative Points
-
Catalog products, about 60% of revenue, grew only mid-single-digits year-to-date, with headwinds from cell and gene therapy and contract manufacturing biopharma end markets, which may persist until early-stage funding recovers.
-
Operating expenses increased to $8.0 million from $7.2 million, driven by investments in sales and marketing, and are expected to be at least $8 million in Q4 2026, impacting near-term profitability.
-
The company remains unprofitable, with a net loss of $3.5 million in Q3 2026, and adjusted EBITDA positive is not expected until annualized revenue reaches $52-$57 million, with a positive adjusted EBITDA quarter targeted before the end of 2027.
-
Revenue growth is partly dependent on biotech funding trends, which, while up 70% trailing 12-month, have not yet flowed to early-stage discovery work, creating uncertainty around the durability of the recovery.
-
Clinical Solutions revenue is lumpy due to larger average order sizes, and the timing of customer progression through clinical trials and commercial phases can cause quarter-to-quarter variability, potentially affecting financial predictability.
Q & A Highlights
Q: Can you quantify how broad the uplift from improving biotech funding was across customers, indications, and order sizes, and what gives you confidence this is a durable trend? A: CEO Stephen Gunstream said it is early but encouraging, as the uptick is broad-based across all modalities servednot just cell and gene therapy but also monoclonal antibodies and other therapeuticsand related specialty CDMOs have picked up as well. He noted the early-stage discovery business has not yet recovered, which is why catalog growth remains muted, but later-stage therapeutic companies that received funding earlier in 2026 are now putting it to work. He wants another couple of quarters of confirmation but is excited about the current position.
Q: Clinical Solutions revenue rose 86% in the quarter. How should we think about growth contributions from this business into 2027 and beyond, especially as you expect to support at least one commercial therapy by the end of next year? A: CFO Matt Lowell said Q4 should continue to show strength in GMP given current trends, while Lab Essentials will not grow at that level. He noted some customers are moving through clinical trial phases, which should benefit 2027, along with the hoped-for impact of increased biotech funding. Longer term, he expects Clinical Solutions to be the bigger growth driver needed to reach the sustainable 20% to 25% growth level, with Lab Essentials providing a strong foundation.
Q: How much of the Clinical Solutions strength is larger pharma versus smaller pharma, and do you anticipate another bump once earlier-stage pharma and biotech funding flows next year? A: CEO Stephen Gunstream noted Clinical Solutions also includes a diagnostics piece that has been a nice growth driver in 2026 and should continue into 2027. He said the biotech funding recovery is mostly from small and mid-sized biotech companies, not large pharmalarge pharma is doing well in catalog, while small and mid-sized biotech is not on catalog, which he attributes to discovery-type R&D work. If funding continues, he believes discovery catalog business from small and mid-sized biotech should migrate back.
Q: Regarding M&A, do you have a target list, and is this near term or opportunistic? A: CEO Stephen Gunstream said the company has had a target list for a long time, and the question is fit, valuation, and executability. He emphasized discipline, noting the company has built infrastructure that can absorb significant scale and expects to reach profitability in a relatively short period. He said a number of targets fit, but many are smaller organizations requiring time to build relationships and confirm valuation makes sensethey must be the right fit.
Q: Can you expand on adjacent areas you'd pursue with the $40 million in cash proceeds, such as proteins? A: CEO Stephen Gunstream said the lowest-risk opportunities are businesses similar to Teknova that can be brought in-house and run through existing manufacturing, dropping profitability to the bottom line. The next step out is additional modalities, with proteins a broad category including enzymes for diagnostics, antibodies, cytokines, or growth factors. He stressed the company will not acquire a business that needs a lot of cash to operate, focusing instead on cost synergies and leveraging existing infrastructure.
Q: Are there areas where spending remains soft, and what needs to change for those customers to return to spending? A: CEO Stephen Gunstream pointed to the discovery side, where some cell and gene therapy companies are not doing much or are declining. Companies with later-stage therapies can raise capital and deploy it, while others are waiting for approvals or their next phase before raising money. He said a real change would require more sustained biotech funding and capital markets opening to riskier upfront investments in new targets, which has not yet happened; large pharma discovery is doing well, but small and mid-sized biotechs are not.
Q: On diagnostics demand, how much is new customers versus existing customers ramping, and how durable is that demand into 2027? A: CEO Stephen Gunstream said on the tools and diagnostics side, the majority of customers having a material impact are existing customers who have been with Teknova for some time and are now scaling up, some tied to AI and data generation and some to liquid biopsy. He noted these are typically two- to three-year processes coming to fruition rather than new logos driving immediate growth, and if customers' products succeed in the market, significant scale-up is expected over coming years.
Q: How much are BuildTek and FilTek additional channels versus true incremental revenue drivers for 2027? A: CEO Stephen Gunstream put them in separate categories. BuildTek streamlines upfront custom order design and specification collection, generating quotes within 24 to 48 hours and translating to revenue typically a quarter or two later; he expects most new custom quote requests to migrate to that channel, with newer customers who had not previously been quoted customs driving a nice build. FilTek addresses customer requests for combining different bag sizes and connectors into a single lot, getting in earlier with lower minimum orders and creating stickiness tied to manufacturing scale; meaningful revenue is likely a couple of years out as early adopters scale through clinical trials.
Q: Does the new capital raise change your investment plan, and should we expect a step-up in commercial spend in 2027 that could affect the timing of the first positive adjusted EBITDA quarter? A: CFO Matt Lowell said the additional capital strengthens the balance sheet but does not in itself change how the company thinks about investing. Commercial investment remains important, and management is currently discussing whether to increase it, though any increase would be incremental rather than of a huge magnitude and would be reported on the next call. He said the capital provides flexibility for larger opportunities such as M&A or organic investments, while the business continues to run as before.
Q: Gross margins were strong in the quarter. What factors are driving the improvement, and what is the updated 2026 gross margin outlook? A: CFO Matt Lowell reiterated a full-year 2026 gross margin target in the mid to high 30s percentage range, with Q4 expected to look similar. Drivers include revenue growth leveraging fixed costs at roughly a 70% marginal cash drop-through, plus a Q3 benefit from higher finished goods inventory that absorbed costs onto the balance sheet rather than the P&L. He noted timing of supply purchases and customer/product mix can cause quarter-to-quarter variability, but over longer periods these smooth out and gross margin should increase nicely over time.
Q: Lab Essentials growth has been around 10%
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
